<DOC>
	<DOCNO>NCT00444639</DOCNO>
	<brief_summary>The active ingredient Pamorelin® 11,25 mg Triptorelin . Triptorelin substitute natural hormone produce body call Gonadotrophin-releasing hormone ( GnRH ) . GnRH hormone secrete hypothalamus ( gland locate brain ) control production sex hormone ( eg testosterone men ) organs body . The growth prostate cancer cell , one common cancer men , induce hormone testosterone . Hormonotherapy one treatments available treat type disease control testosterone serum level . Pamorelin® 11,25 mg normally injected muscle type injection suitable every patient . Therefore primary purpose study assess non-inferiority 12-week triptorelin formulation Pamorelin® 11,25 mg administer via subcutaneous ( SC ) injection compare Pamorelin® 11,25 mg administer via standard intramuscular ( IM ) injection base percentage patient present testosterone level ≤ 50 ng/dl week 24 .</brief_summary>
	<brief_title>Study Assess Non-inferiority Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected Patients Suffering From Advanced Prostate Cancer ( PAMOJECT )</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<criteria>Histological proven prostate cancer , locally advanced metastatic schedule receive hormonal deprivation therapy Life expectancy 9 month Documented testosterone level ≥ 125 ng/dl measure laboratory site within previous 6 month Has history hypersensitivity Investigational Medicinal Product drug similar chemical structure Has previously receive GnRH analogue , estrogens steroidal anti androgen within last year precede study Concomitant anticoagulation treatment Patient underwent orchidectomy schedule receive orchidectomy course study Patient know spinal medullar compression</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>